Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Eric Paul Winer, M.D.

Co-Author

This page shows the publications co-authored by Eric Winer and Craig Bunnell.
Connection Strength

1.303
  1. Bunnell CA, Winer EP. Lumping versus splitting: the splitters take this round. J Clin Oncol. 2002 Sep 01; 20(17):3576-7.
    View in: PubMed
    Score: 0.286
  2. Bunnell CA, Winer EP. Oral 5-FU analogues in the treatment of breast cancer. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):39-43.
    View in: PubMed
    Score: 0.218
  3. Bunnell CA, Gross AH, Weingart SN, Kalfin MJ, Partridge A, Lane S, Burstein HJ, Fine B, Hilton NA, Sullivan C, Hagemeister EE, Kelly AE, Colicchio L, Szabatura AH, Winer EP, Salisbury M, Mann S. High performance teamwork training and systems redesign in outpatient oncology. BMJ Qual Saf. 2013 May; 22(5):405-13.
    View in: PubMed
    Score: 0.147
  4. Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7.
    View in: PubMed
    Score: 0.089
  5. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95.
    View in: PubMed
    Score: 0.076
  6. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003 Jun 15; 97(12):2972-7.
    View in: PubMed
    Score: 0.076
  7. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 01; 21(1):46-53.
    View in: PubMed
    Score: 0.073
  8. Burstein HJ, Bunnell CA, Winer EP. New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol. 2001 Aug; 28(4):344-58.
    View in: PubMed
    Score: 0.066
  9. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
    View in: PubMed
    Score: 0.065
  10. Partridge AH, Bunnell CA, Winer EP. Quality of life issues among women undergoing high-dose chemotherapy for breast cancer. Breast Dis. 2001; 14:41-50.
    View in: PubMed
    Score: 0.064
  11. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9.
    View in: PubMed
    Score: 0.060
  12. Tolaney SM, Najita J, Sperinde J, Huang W, Chen WY, Savoie J, Fornier M, Winer EP, Bunnell C, Krop IE. A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol. 2013 Jul; 24(7):1841-1847.
    View in: PubMed
    Score: 0.037
  13. Meyerhardt JA, Heseltine D, Campos H, Holmes MD, Willett WC, Winer EP, Enzinger PC, Bunnell CA, Kulke MH, Fuchs CS. Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8453-60.
    View in: PubMed
    Score: 0.022
  14. Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):496-504.
    View in: PubMed
    Score: 0.022
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.